NCT05609825

A Study of LY3875383 in Healthy Participants and Participants With Hypertriglyceridemia

A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3875383 in Healthy Participants and Participants With Hypertriglyceridemia

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 41 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to determine the tolerability and side effects related to LY3875383 given as a single injection under the skin to healthy participants and participants with elevated triglyceride (TG) levels.The study will also assess how fast LY3875383 gets into the blood stream and how long the body takes to get rid of it. Each enrolled participant will receive a single dose of either LY3875383 or placebo.The study will be conducted in four parts (A, B, C and D) and may last up to approximately 28 to 56 weeks including screening.

Conditions

• Hypertriglyceridemia

Interventions

Type	Name	Description
DRUG	LY3875383	Administered SC.
DRUG	Placebo	Administered SC.

Timeline

• Start date: 2022-11-14
• Primary completion: 2024-01-10
• Completion: 2024-01-10
• First posted: 2022-11-08
• Last updated: 2025-06-04

Locations

1 site across 1 country: Singapore

Regulatory

• FDA-regulated drug study